CSRxP Applauds FDA’s Focus on REMS Abuses

The Campaign for Sustainable Rx Pricing released the following statement attributable to CSRxP spokesman Will Holley:

“Today’s FDA guidance is a step in the right direction towards our common goal of lowering out-of-control drug prices. When generic and biosimilar competition is thwarted by these abusive tactics, brand-name manufacturers, who alone control the price of their drugs, keep those prices artificially high. The problem is the price, and more competition is a proven solution.

“While we believe that it will take Congressional action on the bipartisan CREATES Act to ultimately put an end to these practices, Commissioner Gottlieb and the FDA should be commended for their action on this important issue.”